Infliximab and Colchicine Therapy in the Treatment of Systemic Secondary Amyloidosis in Crohn’s Disease

You, Geoffrey; Ferges, William; Das, Kiron M.

doi:10.14309/00000434-201410002-01502

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chronic colitis is a key factor of the colorectal cancer. In previous study, the colchicine may play an auxiliary for management of the chronic colitis such as Crohn’s disease with amyloidosis in young adult, perhaps leading to the lower risk of the colorectal cancer in accordance with our findings [ 3 , 50 , 51 ].…”

Section: Discussionsupporting

confidence: 92%

The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

Yeh,

Liw,

Wong

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background To determine the effect of colchicine on cancer risk in patients with the immune-mediated inflammatory diseases (IMIDs)-related to colchicine use. Methods This is a time-dependent propensity-matched general population study based on the National Health Insurance Research Database (NHIRD) of Taiwan. We identified the IMIDs patients (n = 111,644) newly diagnosed between 2000 and 2012 based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)—274,712, 135, 136.1, 279.49, 518.3, 287.0, 696.0, 696.1, 696.8, 420, 429.4, 710.0, 710.1, 710.3, 710.4, 714.0, 720, 55.0, 55.1, 55.9, 556. Inclusion criteria: aged ≧ 20 years, if a patient had at least these disease diagnosis requirements within 1 year of follow-up, and, these patients had at least two outpatient visits or an inpatient visit. After propensity-matched according to age, sex, comorbidities, medications and index date, the IMIDs patients enter into colchicine users (N = 16,026) and colchicine nonusers (N = 16,026). Furthermore, time-dependent Cox models were used to analyze cancer risk in propensity-matched colchicine users compared with the nonusers. The cumulative cancer incidence was analyzed using Cox proportional regression analysis. We calculated adjusted hazard ratios (aHRs) and their 95% confidence intervals (95% CIs) for cancer after adjusting for sex, age, comorbidities, and use of medicine including acetylcysteine, medication for smoking cessation such as nicotine replacement medicines (the nicotine patch) and pill medicines (varenicline), anti-inflammatory drugs and immunosuppressant drugs. Results Comparing the colchicine nonusers, all cancer risk were mildly attenuated, the (aHR (95% CI)) of all cancer is (0.84 (0.55, 0.99)). Meanwhile, the colchicine users were associated with the lower incidence of the colorectal cancer, the (aHRs (95% CI)) is (0.22 (0.19, 0.89)). Those aged < 65 years and male/female having the colchicine users were associated with lower risk the colorectal cancer also. Moreover, the colchicine > 20 days use with the lower aHR for colorectal cancer. Conclusion Colchicine was associated with the lower aHR of the all cancer and colorectal cancer formation in patients with the IMIDs.

show abstract

Section: Discussionsupporting

confidence: 92%

The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

Yeh,

Liw,

Wong

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…The chronic colitis is a key factor of the colorectal cancer. In previous study, the colchicine may play an auxiliary for management of the chronic colitis such as Crohn's disease with amyloidosis in young adult, perhaps leading to the lower risk of the colorectal cancer in accordance with our ndings [3,34,35].…”

Section: Discussionsupporting

confidence: 86%

Effect of colchicine on cancer risk in patients with the musculoskeletal system and connective tissue and rheumatism-related diseases

Yeh,

Liw,

Wong

et al. 2024

Preprint

View full text Add to dashboard Cite

Background To determine the effect of colchicine on cancer risk in patients with the musculoskeletal system and connective tissue and rheumatism-related diseases (MD).Methods We retrospectively enrolled patients with the MD divided them into colchicine users (N = 16,026) and colchicine nonusers (N = 16,026). Furthermore, time-dependent Cox models were used to analyze cancer risk in propensity-matched colchicine users compared with the nonusers. The cumulative cancer incidence was analyzed using Cox proportional regression analysis. We calculated adjusted hazard ratios (aHRs) and their 95% confidence intervals (CIs) for cancer after adjusting for sex, age, comorbidities, and use of medicine including acetylcysteine, medication for tobacco use, anti-inflammatory drugs and immunosuppressant drugs.Results Comparing the colchicine nonusers, only the colchicine users were associated with the lower incidence of the colorectal cancer ( (aHRs) (95% CI), 0.52 (0.49, 0.89)). Notably, the frequency of the medical services may inflate the aHR of brain tumor ((aHRs (95% CI), 8.42 (1.32, 53.9)). However, the aged < 65 years adult having the colchicine users were associated with lower risk the colorectal cancer. Moreover, the colchicine > 20 days use with the lower aHR for colorectal cancer.Conclusion This study implied colchicine with an auxiliary role for protecting the colorectal cancer formation in patients with the musculoskeletal system and connective tissue and rheumatism-related diseases.

show abstract

Infliximab and Colchicine Therapy in the Treatment of Systemic Secondary Amyloidosis in Crohn’s Disease

Cited by 2 publications

References 0 publications

The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan’s National Health Insurance Research Database

Effect of colchicine on cancer risk in patients with the musculoskeletal system and connective tissue and rheumatism-related diseases

Contact Info

Product

Resources

About